Abstract: The present invention relates to the use of N-linked glycan profiles of blood or blood component proteins as biomarkers for diagnosing diabetes mellitus and for monitoring the efficacy of anti-diabetic therapy. Specifically, the present invention relates to detecting changes in the amounts of N-linked glycans as diagnostic biomarkers for diabetes mellitus and as indicators of the efficacy of anti-diabetic therapy over time.

Abstract: The use of N-linked glycosylation pattern of serum proteins as a biomarker for evaluating the efficacy of intervention therapies for diabetes is disclosed. As disclosed herein, changes in the N-linked glycosylation of total plasma proteins precedes and predicts the decrease in glycated hemoglobin (HbA1c) associated with successful treatment of diabetes. Therefore, measuring changes in N-linked glycosylation of total serum plasma proteins over time may be used as a biomarker to evaluate or access the efficacy of an intervention therapy for diabetes.

Abstract: The present invention relates to the use of N-linked glycan profiles of blood or blood component proteins as biomarkers for diagnosing diabetes mellitus and for monitoring the efficacy of anti-diabetic therapy. Specifically, the present invention relates to detecting changes in the amounts of N-linked glycans as diagnostic biomarkers for diabetes mellitus and as indicators of the efficacy of anti-diabetic therapy over time.

Abstract: The present invention provides a novel method for diagnosing renal cell carcinoma. The method of the invention allows evaluation of the presence of renal cell carcinoma or the degree of malignancy of renal cell carcinoma, by conducting comprehensive analysis of N-linked sugar chains in serum of a patient and utilizing an expression level of detected sugar chain as an index of the evaluation.